Maryam Lustberg, Director of the Center for Breast Cancer at Yale University School of Medicine, shared on LinkedIn:
“Thank you to Lynn Sage Breast Cancer Foundation for opening the conference with a focus on menopause concerns of in patients diagnosed with breast cancer and the opportunity of speak with Lisa Larkin OncoMenopause Consortium.
- Breast cancer is not one disease: the answer differs for previvors, DCIS, TNBC, and ER+ disease on therapy.
- Not all hormone therapy is the same: route, type, and duration all change the risk
- Vaginal estrogen: discuss it, start low, acknowledge the aromatase inhibitor data gap, and don’t withhold it.
- Questions about testosterone are coming. As an oncology community we need shared recommendations on testosterone and other hormones. See National Comprehensive Cancer Network (NCCN) footnote on this.
- New risk adapted guidelines in press as part of a modified Delphi panel with oncology and women’s health represented
Listen, then personalize, being clear about the data gaps and about what we know of recurrence biology and risk.”
You can also read:
